ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
FDA Approves Imbruvica Plus Rituximab
americanpharmaceuticalreview
August 28, 2018Janssen Pharmaceutical announced the U.S. Food and Drug Administration (FDA) approval of Imbruvica (ibrutinib) in combination with rituximab for the treatment of Waldenstr?m's macroglobulinemia (WM), a rare blood cancer.
Pharma Sources Insight January 2025
